Tumor-associated myeloid cells have been shown to modulate the responsiveness and resistance to antiangiogenic therapy, in part by stimulating VEGF-independent pathways, as well as the production of angiogenic chemokines and cytokines44. Here, VEGFA is linked to neoplasm.